Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025
Rhea-AI Summary
Invivyd (Nasdaq: IVVD) will host a conference call on Thursday, November 6, 2025 at 8:30 a.m. ET to discuss third quarter 2025 financial results and provide a corporate update.
Interested parties may join the live webcast via the company's investor relations site and are advised to log in about 15 minutes before the start. A recording will be available on the investor relations website shortly after the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, IVVD declined 8.52%, reflecting a notable negative market reaction. Argus tracked a trough of -26.1% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $35M from the company's valuation, bringing the market cap to $377M at that time.
Data tracked by StockTitan Argus on the day of publication.
NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, November 6, 2025, at 8:30 a.m. ET to discuss its third quarter 2025 financial results and provide a corporate update.
Interested parties may join the live webcast by visiting this link and are advised to log in approximately 15 minutes prior to the start of the call. A recording of the webcast will be available on the company’s investor relations website shortly after the event.
About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
Contacts:
Media Relations
(781) 208-0160
media@invivyd.com
Investor Relations
(781) 208-1747
investors@invivyd.com
FAQ
When is Invivyd's (IVVD) Q3 2025 earnings call scheduled?
How can I access the Invivyd (IVVD) November 6, 2025 webcast?
Will Invivyd (IVVD) provide a replay of the Q3 2025 call?
What will Invivyd (IVVD) discuss on the November 6, 2025 call?
Do I need to register before joining the Invivyd (IVVD) webcast on November 6, 2025?
Where can investors find the Q3 2025 presentation materials for Invivyd (IVVD)?
